Skip to main content
. Author manuscript; available in PMC: 2017 Jun 13.
Published in final edited form as: Cold Spring Harb Symp Quant Biol. 2017 Jan 5;81:257–267. doi: 10.1101/sqb.2016.81.031096

Figure 3.

Figure 3

Ponatinib in combination with trametinib leads to tumor regression of KRAS-mutant lung tumors. Representative µCT images of the lungs of KrasG12D; Trp53−/− genetically engineered mice treated with vehicle, trametinib (3 mg/kg), ponatinib (30 mg/kg), or both drugs in combination for the indicated times. Lung tumors are indicated by yellow arrows and red asterisks mark the hearts. All mouse experiments were approved by the Memorial Sloan Kettering Cancer Center (MSKCC) Animal Care and Use Committee (protocol no. 12-04-006).